Skip to main content
Top
Published in: Cancer Causes & Control 5/2009

01-07-2009 | Original Paper

Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia

Authors: Deborah Randall, Stephen Morrell, Richard Taylor, Wai Tak Hung

Published in: Cancer Causes & Control | Issue 5/2009

Login to get access

Abstract

Objective

This study examined whether offering annual mammography screening for women with the risk factor of a family history of breast cancer resulted in more favorable prognostic indicators of diagnosed cancers than the usual approach of biennial screening.

Methods

The study involved women aged 50–69 years with a family history of breast cancer, defined as having ≥1 first-degree relative diagnosed with breast cancer, who were diagnosed with a screen-detected invasive breast cancer between 1998 and 2004 in BreastScreen New South Wales (n = 590). The women were grouped according to whether they screened in an area offering annual screening to women with a family history, or were offered the standard biennial screening. The odds of having favorable tumor size, grade, and nodal status prognosis were compared between these screening groups using logistic regression. A comparison group of women without a family history, all offered biennial screening, was also evaluated based on the same area groupings to examine whether any differences were due to the area, rather than the screening interval policy.

Results

Women with a family history who were offered annual screening at BreastScreen NSW were significantly more likely than those who were offered biennial screening to be diagnosed with a tumor ≤20 mm in size (adjusted odds ratio (AOR) = 1.91, 95% CI: 1.21–3.02), and to have a node-negative tumor (AOR = 1.61, 95% CI: 1.03–2.50). There were also significantly higher odds of being diagnosed with tumors ≤15 mm (p < 0.001) and ≤10 mm in size (p = 0.011) in women offered annual screening. There was no significant difference in the odds of a Grade 1 tumor being detected (AOR = 1.26, 95% CI: 0.87–1.81), although the direction of the effect was consistent with that seen for size and nodal status. No significant differences were found in the comparison group of women without a family history.

Conclusions

Offering annual screening for women aged 50–69 years with a family history of breast cancer significantly increased the odds of being diagnosed with a smaller, node-negative tumors. Further investigation is required to assess whether the improved prognostic indicators translate into significantly better mortality outcomes for women with a family history offered annually screening.
Literature
3.
go back to reference Breast Cancer Screening (2002) In: Vainio H, Bianchini F (eds) IARC handbooks of cancer prevention, vol 7. IARC Press, Lyon, France Breast Cancer Screening (2002) In: Vainio H, Bianchini F (eds) IARC handbooks of cancer prevention, vol 7. IARC Press, Lyon, France
4.
go back to reference Kerlikowske K, Carney PA, Geller B et al (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133:855–863PubMed Kerlikowske K, Carney PA, Geller B et al (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Intern Med 133:855–863PubMed
8.
go back to reference Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399. doi:10.1016/S0140-6736(01)06524-2 CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389–1399. doi:10.​1016/​S0140-6736(01)06524-2 CrossRef
9.
go back to reference Australian Institute of Health and Welfare (2007) BreastScreen Australia monitoring report, 2003–2004. AIHW cat. no. CAN 31,. AIHW, Canberra Australian Institute of Health and Welfare (2007) BreastScreen Australia monitoring report, 2003–2004. AIHW cat. no. CAN 31,. AIHW, Canberra
10.
go back to reference Breast Tumours (1997) In: Sobin LH, Wittekind Ch (eds) UICC TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York, pp 123–130 Breast Tumours (1997) In: Sobin LH, Wittekind Ch (eds) UICC TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York, pp 123–130
11.
go back to reference Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn H-J, Panel Members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583. doi:10.1093/annonc/mdi326 PubMedCrossRef Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn H-J, Panel Members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583. doi:10.​1093/​annonc/​mdi326 PubMedCrossRef
14.
go back to reference Lai MS, Yen MF, Kuo HS, Koong SL, Chen TH, Duffy SW (1998) Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 78:21–26. doi:10.1002/(SICI)1097-0215(19980925)78:1<21::AID-IJC5>3.0.CO;2-ZPubMedCrossRef Lai MS, Yen MF, Kuo HS, Koong SL, Chen TH, Duffy SW (1998) Efficacy of breast-cancer screening for female relatives of breast-cancer-index cases: Taiwan multicentre cancer screening (TAMCAS). Int J Cancer 78:21–26. doi:10.1002/(SICI)1097-0215(19980925)78:1<21::AID-IJC5>3.0.CO;2-ZPubMedCrossRef
15.
go back to reference Tabar L, Fagerberg G, Chen H, Duffy SW, Smart C, Smith RA (1995) Efficacy of breast cancer screening by age. Cancer 75:2507–2517. doi:10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-HPubMedCrossRef Tabar L, Fagerberg G, Chen H, Duffy SW, Smart C, Smith RA (1995) Efficacy of breast cancer screening by age. Cancer 75:2507–2517. doi:10.1002/1097-0142(19950515)75:10<2507::AID-CNCR2820751017>3.0.CO;2-HPubMedCrossRef
16.
go back to reference Nixon RM, Pharoah P, Tabar L et al (2000) Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. Rev Epidemiol Sante Publique 48(4):325–331PubMed Nixon RM, Pharoah P, Tabar L et al (2000) Mammographic screening in women with a family history of breast cancer: some results from the Swedish two-county trial. Rev Epidemiol Sante Publique 48(4):325–331PubMed
20.
go back to reference White E, Miglioretti DL, Yankaskas BC et al (2004) Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst 96(24):1832–1839PubMedCrossRef White E, Miglioretti DL, Yankaskas BC et al (2004) Biennial versus annual mammography and the risk of late-stage breast cancer. J Natl Cancer Inst 96(24):1832–1839PubMedCrossRef
26.
go back to reference Kent F, Hoskins KF, Zwaagstra A, Ranz M (2006) Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer 107(8):1769–1776. doi:10.1002/cncr.22202 CrossRef Kent F, Hoskins KF, Zwaagstra A, Ranz M (2006) Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer 107(8):1769–1776. doi:10.​1002/​cncr.​22202 CrossRef
Metadata
Title
Annual or biennial mammography screening for women at a higher risk with a family history of breast cancer: prognostic indicators of screen-detected cancers in New South Wales, Australia
Authors
Deborah Randall
Stephen Morrell
Richard Taylor
Wai Tak Hung
Publication date
01-07-2009
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 5/2009
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-008-9264-0

Other articles of this Issue 5/2009

Cancer Causes & Control 5/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine